Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Pipeline Review, H2 2016
"Nociceptin
Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ
Receptor or OPRL1) - Pipeline Review, H2 2016"
The Report covers current Market Trends, Analysis, Forecast, Review,
Share, Size, Growth, Effect.
Description-
Summary
Global
Markets Directs, Nociceptin Receptor (Kappa Type 3 Opioid Receptor or
KOR3 or Orphanin FQ Receptor or OPRL1) - Pipeline Review, H2 2016,
provides in depth analysis on Nociceptin Receptor (Kappa Type 3
Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted
pipeline therapeutics.
The
report provides comprehensive information on the Nociceptin Receptor
(Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or
OPRL1), targeted therapeutics, complete with analysis by indications,
stage of development, mechanism of action (MoA), route of
administration (RoA) and molecule type. The report also covers the
descriptive pharmacological action of the therapeutics, its complete
research and development history and latest news and press releases.
Additionally, the report provides an overview of key players involved
in Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or
Orphanin FQ Receptor or OPRL1) targeted therapeutics development and
features dormant and discontinued projects.
Scope
-
The report provides a snapshot of the global therapeutic landscape
for Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or
Orphanin FQ Receptor or OPRL1)
-
The report reviews Nociceptin Receptor (Kappa Type 3 Opioid Receptor
or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics under
development by companies and universities/research institutes based
on information derived from company and industry-specific sources
-
The report covers pipeline products based on various stages of
development ranging from pre-registration till discovery and
undisclosed stages
-
The report features descriptive drug profiles for the pipeline
products which includes, product description, descriptive MoA, R&D
brief, licensing and collaboration details & other developmental
activities
Reasons
to buy
-
Gain strategically significant competitor information, analysis, and
insights to formulate effective R&D strategies
-
Identify emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive advantage
-
Identify and understand the targeted therapy areas and indications
for Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or
Orphanin FQ Receptor or OPRL1)
-
Identify the use of drugs for target identification and drug
repurposing
-
Identify potential new clients or partners in the target demographic
Comments
Post a Comment